Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK11 | Q15759 | 20/20 | 0.63 |
| ▸ | MAPK14 | Q16539 | 20/20 | 0.63 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.59 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL239606 | 0.89 | MAPK11 (0.67) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL244356 | 0.85 | MAPK11 (0.63) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL243751 | 0.85 | MAPK11 (0.70) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL239375 | 0.83 | MAPK14 (0.60) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL241982 | 0.82 | HDAC1 (0.68) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL240047 | 0.81 | MAPK11 (0.64) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL178563 | 0.81 | MEN1 (0.68) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL10090777 | 0.81 | MAPK11 (0.60) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL243758 | 0.81 | MAPK11 (0.60) | MAPK11MAPK14MAPK13MAPK12 | |
| SCHEMBL12676759 | 0.80 | MAPK11 (0.65) | MAPK11MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742124-B2 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2014-06-03 | — | — | US | disclosed |
| US-20130035346-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2013-02-07 | — | — | US | disclosed |
| US-20120004243-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | ASTRAZENECA AB (SE) | 2012-01-05 | — | — | US | disclosed |
| US-7943776-B2 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASRAZENECA AB (SE) | 2011-05-17 | — | — | US | disclosed |
| US-20070135440-A1 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | ASTRAZENECA AB (SE) | 2007-06-14 | — | — | US | disclosed |
| EP-1699766-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | AstraZeneca AB (SE) | 2006-09-13 | — | — | EP | disclosed |
| WO-2005061465-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTO KINE INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135440-A1 | Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors | IL2, IL6, IL1B | MAPK11 2179/4885MAPK14 1549/4885MAPK13 2573/4885 |
| US-20120004243-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | IL2, IL6, IL1B | MAPK11 2262/4885MAPK14 1594/4885MAPK13 2611/4885 |
| US-20130035346-A1 | AMIDE DERIVATIVES BEARING A CYCLOPROPYLAMINOACARBONYL SUBSTITUENT USEFUL AS CYTOKINE INHIBITORS | IL2, IL6, IL1B | MAPK11 2262/4885MAPK14 1594/4885MAPK13 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.